Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Corporate Webcast: Apogenix GmbH APG101 – A Novel Approach For The Treatment Of Cancer.

Apogenix GmbH APG101 - A Novel Approach for the Treatment of Cancer.

APG101 is a human fusion protein consisting of the extracellular domain of the CD95 receptor fused to the IgG part of an antibody. It binds to the CD95 ligand, thereby blocking the interaction with its cognate receptor. Whereas this interaction triggers apoptosis in many cells, it stimulates invasive growth in cancer cells. Blocking CD95 mediated tumor growth thus represents a novel concept to treating cancer.

Broadcast live, record and publish your investor, corporate and analyst videos on 3B NEXUS for our targeted distribution.